contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

Biohit

Biohit announced on Thursday that it has signed a distribution agreement with Biomedal for the distribution of celiac disease diagnostic tests in selected European countries.

Translation: Original published in Finnish on 1/17/2025 at 7:09 am EET. 
Biohit&#xa0;<a href="https://www.inderes.se/en/releases/biohit-secures-european-distribution-rights-for-biomedals-gluten-immunogenic-peptide-tests">announced</a> on Thursday that it has signed a distribution agreement with Biomedal for the distribution of celiac disease diagnostic tests in selected European countries. The distribution agreement complements Biohit&apos;s product portfolio, which already includes a quick test for celiac disease. We expect modest revenues from the distribution agreement and the news is in line with our strong growth projections.
<h2>The agreement complements Biohit&#x2019;s product portfolio </h2>
The agreement with Biomedal concerns diagnostic tests for the detection of gluten immunogenic peptides that activate the immune response in celiac disease. The tests provide a quick and patient-friendly solution for celiac disease patients to monitor their gluten intake. The tests can be used by both healthcare professionals and patients. The agreement provides Biohit with exclusive distribution rights for Biomedal&apos;s quick test and immunoassays portfolio in the Netherlands, Ireland, Norway, Portugal, France, Sweden, Finland, Switzerland, Denmark, Czech Republic, Hungary and the United Kingdom. Biohit also receives non-exclusive rights in all European countries except Italy and Spain. The agreement expands Biohit&apos;s product portfolio. In terms of commercial potential, we expect the new products to have a moderate impact on revenue. We understand that the majority of Biohit&apos;s revenue is generated from sales of the GastroPanel&#xae; product family.
<h2>Fast growth expected in the coming years</h2>
Biohit is targeting strong annual growth of 15-20% over the strategy period 2024-2028. Our forecasts also predict strong growth. The news of the increase in the number of products sold is therefore in line with our expectations and does not lead to any changes in our forecasts at this stage. Biohit will publish its financial statements on February 12, which will provide more detailed information on the company&apos;s development.&#xa0;

	2023	24e	25e
Revenue	13.1	14.3	17.6
growth-%	19.2 %	9.8 %	22.7 %
EBIT (adj.)	1.8	2.4	2.8
EBIT-% (adj.)	13.4 %	17.0 %	15.7 %
EPS (adj.)	0.12	0.15	0.16
Dividend	0.00	0.00	0.04
Dividend %			1.4 %
P/E (adj.)	16.6	18.4	17.8
EV/EBITDA	11.7	12.6	10.6

New distribution rights for Biohit

The agreement complements Biohit’s product portfolio

Fast growth expected in the coming years

Biohit

Key Estimate Figures15.01